

Christoforos Thomas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8618836/publications.pdf>

Version: 2024-02-01

23
papers

1,141
citations

623734

14
h-index

677142

22
g-index

23
all docs

23
docs citations

23
times ranked

2131
citing authors

#	ARTICLE	IF	CITATIONS
1	The different roles of ER subtypes in cancer biology and therapy. <i>Nature Reviews Cancer</i> , 2011, 11, 597-608.	28.4	555
2	ER α 1 represses basal-like breast cancer epithelial to mesenchymal transition by destabilizing EGFR. <i>Breast Cancer Research</i> , 2012, 14, R148.	5.0	73
3	Estrogen-dependent DLL1-mediated Notch signaling promotes luminal breast cancer. <i>Oncogene</i> , 2019, 38, 2092-2107.	5.9	66
4	Estrogen receptor mutations and functional consequences for breast cancer. <i>Trends in Endocrinology and Metabolism</i> , 2015, 26, 467-476.	7.1	63
5	Pharmaceutical Agents Known to Produce Disulfiram-Like Reaction: Effects on Hepatic Ethanol Metabolism and Brain Monoamines. <i>International Journal of Toxicology</i> , 2007, 26, 423-432.	1.2	54
6	The Two-Pore Domain Potassium Channel KCNK5: Induction by Estrogen Receptor α and Role in Proliferation of Breast Cancer Cells. <i>Molecular Endocrinology</i> , 2011, 25, 1326-1336.	3.7	51
7	ER α 2 decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function. <i>Oncotarget</i> , 2016, 7, 13599-13611.	1.8	39
8	Bcl-2 blocks 2-methoxyestradiol induced leukemia cell apoptosis by a p27Kip1-dependent G1/S cell cycle arrest in conjunction with NF- κ B activation. <i>Biochemical Pharmacology</i> , 2009, 78, 33-44.	4.4	31
9	Progesterone receptor-estrogen receptor crosstalk: a novel insight. <i>Trends in Endocrinology and Metabolism</i> , 2015, 26, 453-454.	7.1	25
10	Estrogen signaling and unfolded protein response in breast cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 163, 45-50.	2.5	23
11	Rosmarinic acid failed to suppress hydrogen peroxide-mediated apoptosis but induced apoptosis of Jurkat cells which was suppressed by Bcl-2. <i>Molecular and Cellular Biochemistry</i> , 2006, 285, 111-120.	3.1	22
12	Combination of CHEK1/2 inhibition and ionizing radiation results in abscopal tumor response through increased micronuclei formation. <i>Oncogene</i> , 2020, 39, 4344-4357.	5.9	22
13	Somatic loss of estrogen receptor beta and p53 synergize to induce breast tumorigenesis. <i>Breast Cancer Research</i> , 2017, 19, 79.	5.0	20
14	ER α 2 alters the chemosensitivity of luminal breast cancer cells by regulating p53 function. <i>Oncotarget</i> , 2018, 9, 22509-22522.	1.8	19
15	ER α 2 Regulates NSCLC Phenotypes by Controlling Oncogenic RAS Signaling. <i>Molecular Cancer Research</i> , 2014, 12, 843-854.	3.4	14
16	ER α 2 Sensitizes NSCLC to Chemotherapy by Regulating DNA Damage Response. <i>Molecular Cancer Research</i> , 2018, 16, 233-242.	3.4	14
17	Effect of intravenous administration of antioxidants alone and in combination on myocardial reperfusion injury in an experimental pig model. <i>Current Therapeutic Research</i> , 2008, 69, 423-439.	1.2	11
18	Characteristics and survival of patients with advanced cancer and p53 mutations. <i>Oncotarget</i> , 2014, 5, 3871-3879.	1.8	11

#	ARTICLE	IF	CITATIONS
19	Not enough evidence to include ESR1 amplification. Nature Reviews Cancer, 2011, 11, 823-823.	28.4	9
20	Estrogen Receptor β -Mediated Inhibition of Actin-Based Cell Migration Suppresses Metastasis of Inflammatory Breast Cancer. Cancer Research, 2021, 81, 2399-2414.	0.9	7
21	A CUE hints at tumor resistance. Nature Medicine, 2011, 17, 658-660.	30.7	6
22	Pleiotropic signaling evoked by tumor necrosis factor in podocytes. American Journal of Physiology - Renal Physiology, 2015, 309, F98-F108.	2.7	6
23	Estrogen Receptor β and Breast Cancer. Cancer Drug Discovery and Development, 2019, , 309-342.	0.4	0